E7386 + Pembrolizumab + Lenvatinib
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Melanoma
Conditions
Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
Trial Timeline
Oct 27, 2021 → Oct 15, 2024
NCT ID
NCT05091346About E7386 + Pembrolizumab + Lenvatinib
E7386 + Pembrolizumab + Lenvatinib is a phase 1/2 stage product being developed by Eisai for Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05091346. Target conditions include Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05091346 | Phase 1/2 | Completed |
Competing Products
20 competing products in Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Binimetinib Oral Tablet | Biotrial | Phase 1 | 25 |
| Tasisulam-sodium + Paclitaxel | Eli Lilly | Phase 3 | 77 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT01 + [68Ga]VMT02 | Perspective Therapeutics | Phase 1 | 25 |
| FYB206 + Keytruda | Formycon AG | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Pre-clinical | 23 |
| PLX3397 + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-8273a + Nivolumab | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| enfortumab vedotin + pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| YM155 | Astellas Pharma | Phase 2 | 52 |
| YM155 + Docetaxel | Astellas Pharma | Phase 2 | 52 |
| Denileukin diftitox | Eisai | Phase 2 | 52 |
| E7080 | Eisai | Phase 1 | 33 |
| lenvatinib + pembrolizumab | Eisai | Phase 2 | 52 |
| MORAb-004 (monoclonal antibody) | Eisai | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Lenvatinib + Dacarbazine | Eisai | Phase 1/2 | 41 |